Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 13;23(1):349.
doi: 10.1186/s12872-023-03167-1.

Predictive value of von Willebrand factor for venous thrombosis in patients with chronic heart failure complicated with atrial fibrillation after anticoagulant therapy

Jinping Song  1 , Yuan Liu  1 , Guohong Huang  2
Affiliations

Predictive value of von Willebrand factor for venous thrombosis in patients with chronic heart failure complicated with atrial fibrillation after anticoagulant therapy

Jinping Song et al. BMC Cardiovasc Disord. .

Abstract

Background: We investigated the value of von Willebrand factor (vWF) in predicting venous thrombosis in patients with chronic heart failure complicated with atrial fibrillation after anticoagulation therapy.

Methods: Totally, 126 patients with chronic heart failure complicated with atrial fibrillation who were treated with anticoagulant therapy and 60 healthy individuals were enrolled. One year after anticoagulant therapy, venous thrombosis occurred in 19 patients. Clinical data of patients were collected. The plasma vWF activity was detected and compared. The logistic regression analysis was used to analyze the influencing factors of vWF. ROC curve was used to evaluate the predictive value of plasma vWF.

Results: Plasma vWF activity was significantly higher in patients with heart failure and atrial fibrillation than control subjects (P < 0.01). The vWF activity in patients with venous thrombosis was significantly higher than that in patients without venous thrombosis (P < 0.01). ROC curve analysis showed that the cut-off value of vWF activity for venous thrombosis within one year after anticoagulant therapy was 267.5%, and the AUC was 0.742 (95% CI: 0.764-0.921, P < 0.05). The sensitivity was 80.0%, and the specificity was 63.6%. Factors of diabetes, myocardial ischemia, old myocardial infarction, and lower extremity atherosclerosis, but not sex, age, coronary heart disease, hypertension, and cardiac function, had significant effect on vWF activity (P < 0.05). Logistic regression analysis showed that vWF activity was significantly related with atherosclerosis of lower limbs and old myocardial infarction, but not significantly related with diabetes and myocardial ischemia. The risk of venous thrombosis in patients with vWF activity greater than 267.5% was 10.667 times higher than that in patients with vWF activity less than 267.5% (P < 0.05).

Conclusion: The vWF activity greater than 267.5% has clinical predictive value for the risk of lower extremity venous thrombosis in patients with chronic heart failure complicated with atrial fibrillation within 1 year of anticoagulant therapy.

Keywords: Anticoagulant therapy; Atrial fibrillation; Chronic heart failure; Venous thrombosis; Von Willebrand factor.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
ROC curve of vWF. Predictive effect of plasma vWF activity on venous thrombosis after anticoagulant therapy in patients with heart failure and atrial fibrillation was evaluated by ROC curve. The sensitivity and specificity were shown
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ambrosio G, Camm AJ, Bassand JP, et al. Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF. ESC Heart Fail. 2021;8(2):1139–49. doi: 10.1002/ehf2.13156. - DOI - PMC - PubMed
    1. Pang Z, Yao Z, Tian L, Pan C. A comparative study on the efficacy of rivaroxaban and warfarin in patients with heart failure and atrial fibrillation aged > 75 years. Chin J Geriatric Heart Brain Vessel Dis. 2018;20(11):1153–6. doi: 10.3969/j.issn.1009-0126.2018.11.008. - DOI
    1. Komajda M, Anker SD, Cowie MR, et al. Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016;18(5):514–22. doi: 10.1002/ejhf.510. - DOI - PubMed
    1. Farmakis D, Chrysohoou C, Giamouzis G, et al. The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Fail Rev. 2021;26(6):1345–58. doi: 10.1007/s10741-020-09978-0. - DOI - PubMed
    1. Stafylas P, Farmakis D, Kourlaba G, et al. The heart failure pandemic: the clinical and economic burden in Greece. Int J Cardiol. 2017;227:923–9. doi: 10.1016/j.ijcard.2016.10.042. - DOI - PubMed

Publication types

MeSH terms